January 12, 2019 - 6:16 AM EST
Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development











Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development

With two candidates at Phase 1 of development and others at a preclinical stage, Alector (ALEC) is a name that only long time investors will appreciate. The company could take many years to report revenues from commercialization. The stock price may increase in 2019 as Alector reports new results. However, the big gains will not arrive until Phase 3 of development is reached. In addition, the company has agreements with large partners, so it should not have liquidity or solvency problems in the near future. The clinical results to be released are what matter the

Read more ...


Source: SeekingAlpha (January 12, 2019 - 6:16 AM EST)